Molecular structure of Apixaban, CAS Number: 503612-47-3
Apixaban (CAS 503612-47-3)
See product citations (2)
Alternate Names:
BMS-562247
Application:
Apixaban is a highly selective, reversible, and direct inhibitor of Factor X
CAS Number:
503612-47-3
Purity:
≥98%
Molecular Weight:
459.50
Molecular Formula:
C25H25N5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Apixaban is a direct inhibitor of factor Xa, an essential component of the coagulation cascade. It functions by selectively binding to both free and clot-bound factor Xa, thereby inhibiting its activity and preventing the conversion of prothrombin to thrombin. This inhibition ultimately leads to the prevention of thrombin formation and subsequent blood clot formation. Apixaban achieves this by targeting the active site of factor Xa, interfering with its ability to interact with its substrates. By doing so, it effectively disrupts the coagulation process and impedes the formation of fibrin clots. This mechanism of action makes apixaban a promising candidate for research and development aimed at understanding and manipulating the coagulation cascade.
Apixaban (CAS 503612-47-3) References
- Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. | Pinto, DJ., et al. 2007. J Med Chem. 50: 5339-56. PMID: 17914785
- Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. | Mavrakanas, TA., et al. 2017. J Am Soc Nephrol. 28: 2241-2248. PMID: 28302754
- International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study. | Ofek, F., et al. 2017. Clin Ther. 39: 1003-1010. PMID: 28476405
- Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. | Chokesuwattanaskul, R., et al. 2018. Pacing Clin Electrophysiol. 41: 627-634. PMID: 29577340
- Apixaban-induced liver injury. | Machlab, S., et al. 2019. Rev Esp Enferm Dig. 111: 161-163. PMID: 30569731
- Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation. | Mavrakanas, TA., et al. 2020. Clin J Am Soc Nephrol. 15: 1146-1154. PMID: 32444398
- Possible apixaban-induced leukocytoclastic vasculitis. | Daul, B., et al. 2020. Am J Health Syst Pharm. 77: 1389-1392. PMID: 32789435
- Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis. | Abdullah, HM., et al. 2021. Cardiovasc Revasc Med. 30: 26-32. PMID: 34420589
- Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): A prospective cohort study. | Merli, GJ., et al. 2022. Vasc Med. 27: 269-276. PMID: 34809507
- Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery. | Kok, T., et al. 2022. Obes Surg. 32: 607-614. PMID: 34822108
- Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. | Dawwas, GK., et al. 2022. Ann Intern Med. 175: 20-28. PMID: 34871048
- Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. | Crouch, A., et al. 2022. Pharmacotherapy. 42: 119-133. PMID: 34904263
- Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation. | Mamas, MA., et al. 2022. Am J Cardiol. 166: 58-64. PMID: 34949473
- Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. | Talmor-Barkan, Y., et al. 2022. Eur Heart J Cardiovasc Pharmacother. 9: 26-37. PMID: 36341531
- Myocardial interaction of apixaban after experimental acute volume overload. | Huuskonen, C., et al. 2022. J Int Med Res. 50: 3000605221137474. PMID: 36397004
Inhibitor of:
β thromboglobulin, ADF, BPNT1, C4b, CapZ-β, CD42c, DIC, Factor IX, Factor V, Factor VII, Factor VIII, Factor X, Factor XII, Factor XIII A, Fibrinogen β, GPVI, HABP2, HPRG, HRG-α, HRG-β1, Na+ CP type IXα, NCAG1, OTTMUSG00000019145, PAcP, PECAM-1, PF-4, PN-1, Protein Z, PT, SerpinA9, TFPI, Thrombin R, and VKORC1.Activator of:
C1INH, HCII, Hirudin, Kininogen, Protein C, TAFI, and TLCK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Apixaban, 10 mg | sc-364406 | 10 mg | $240.00 | |||
Apixaban, 50 mg | sc-364406A | 50 mg | $634.00 |